Harrison W. Farber, MD

Professor, Medicine

(617) 638-4860
72 E. Concord St Housman (R)

Biography

Dr. Farber is considered an opinion leader and internationally recognized expert in the field of pulmonary hypertension. He is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center.

Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury. He has extensive government and private funding and is an NIH-funded Principle Investigator on several grants. He is a member of several research groups both within the Pulmonary Center and in other divisions within the Department of Medicine: the Pulmonary Vascular Biology Group (Pulmonary Center); the Center for Excellence in Sickle Cell Disease (Hematology), the Scleroderma Vascular Disease Group (Rheumatology) and Pulmonary Vascular/Left Ventricular Study Group (Cardiology). Dr. Farber’s laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, with scleroderma, and with left ventricular diastolic dysfunction.

Dr. Farber’s team is developing a database and registry of sickle cell patients with pulmonary hypertension (see Dr. Elizabeth Klings’ faculty profile) as well as a database and registry of scleroderma patients with various forms of pulmonary disease including pulmonary hypertension. They are participating in numerous multi-center clinical trials of new therapies for pulmonary hypertension and have several single-site trials for novel proof of concept therapies for pulmonary hypertension.

Education

  • George Washington University, MD
  • Duke University, BS

Publications

  • Published on 10/2/2017

    Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2017 Oct 02. PMID: 29096938.

    Read at: PubMed
  • Published on 8/3/2017

    Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulm Circ. 2017 Jul-Sep; 7(3):741-746. PMID: 28671485.

    Read at: PubMed
  • Published on 8/3/2017

    Benza RL, Farber HW, Selej M, Gomberg-Maitland M. Assessing risk in pulmonary arterial hypertension: what we know, what we don't. Eur Respir J. 2017 Aug; 50(2). PMID: 28775053.

    Read at: PubMed
  • Published on 3/23/2017

    Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017 Mar 23; 9(1):27. PMID: 28330499.

    Read at: PubMed
  • Published on 12/1/2016

    Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016 Dec; 25(142):418-430. PMID: 27903664.

    Read at: PubMed
  • Published on 11/4/2016

    Sardana M, Moll M, Farber HW. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2016 Dec; 12(12):1513-1520. PMID: 27756196.

    Read at: PubMed
  • Published on 9/1/2016

    Preston IR, Farber HW. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. J Thorac Dis. 2016 Sep; 8(9):E1106-E1107. PMID: 27747077.

    Read at: PubMed
  • Published on 7/27/2016

    Finch KT, Stratton EA, Farber HW. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. J Heart Lung Transplant. 2016 Nov; 35(11):1370-1373. PMID: 27623099.

    Read at: PubMed
  • Published on 6/7/2016

    Cheong FY, Gower AC, Farber HW. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum. 2017 Feb; 46(4):465-472. PMID: 27499522.

    Read at: PubMed
  • Published on 5/17/2016

    Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation. 2016 May 17; 133(20):e662. PMID: 27185031.

    Read at: PubMed

View 190 more publications: View full profile at BUMC

View all profiles